Urinary Tract Infection in Males Treatment & Management

  • Author: John L Brusch, MD, FACP; Chief Editor: Michael Stuart Bronze, MD   more...
 
Updated: Jul 7, 2011
 

Approach Considerations

As a general rule, all urinary tract infections (UTIs) in men are considered complicated; therefore, the possibility that infection has ascended to the kidneys must be considered. Thus, treatment regimens must assume that infection of the upper urinary tract has occurred. Urine culture results allow adjustment of the treatment plan if antibiotic sensitivity testing demonstrates a resistant organism.

In elderly patients, pyelonephritis carries a 3% mortality rate. Take a conservative management approach with these patients.

The decision to treat young men who are sexually active for UTI versus sexually transmitted disease (STD)-related urethritis rests primarily on epidemiologic grounds (eg, recent new sexual partner, multiple sexual partners).

Next

Outpatient vs Inpatient UTI Management

Patients who are well appearing, have stable vital signs, are able to maintain oral hydration and comply with oral therapy, and have no significant comorbid conditions can be treated as outpatients with adequate follow-up arranged in 48-72 hours.

If the patient appears toxic, has obstructive uropathy, has stones, is unable to tolerate fluids by mouth, has significant comorbid disease, or otherwise is unable to care for himself at home, inpatient admission is recommended. For example, consider admission for UTI for elderly patients and patients who have diabetes, who are immunocompromised, or who show signs of dehydration, hyperpyrexia, or rigors.

Initial inpatient treatment includes intravenous (IV) antimicrobial therapy with a third-generation cephalosporin, such as ceftriaxone; a fluoroquinolone, such as ciprofloxacin; or an aminoglycoside. Antipyretics, analgesics, and adequate IV fluids to restore appropriate circulatory volume and promote adequate urinary flow are also important.

Pharmacotherapy

Administer antimicrobial therapy, initially given IV, such as a third-generation cephalosporin, a fluoroquinolone, or an aminoglycoside. In patients with risk factors associated with an unfavorable prognosis, such as old age, debility, renal calculi, recent hospitalization or instrumentation, diabetes, sickle cell anemia, underlying carcinoma, or intercurrent cancer chemotherapy, the antimicrobial coverage should be broadened and an antipseudomonal agent should be added.

Adult males with UTI should receive a 10- to 14-day course of antibiotics. Outpatient regimens include a fluoroquinolone, trimethoprim-sulfamethoxazole (TMP-SMZ), minocycline, or nitrofurantoin (should not be given if glomerular filtration rate < 50). Treat the symptom of dysuria with phenazopyridine.[9, 10, 11, 12]

Unfortunately, the prevalence of uropathogens resistant to TMP-SMZ, nitrofurantoin, and first-generation cephalosporins continue to rise. There are data that suggest overall resistance to TMP-SMZ is approximately 25% (range, 10-45%) based on the area of the country, and resistance to nitrofurantoin is slightly higher. Over the last decade, resistance to fluoroquinolones has been acceptably low in most studies; however, more recent microbiologic data suggest that fluoroquinolone resistance, particularly in the West coast, may be an increasing problem. Despite these concerns, fluoroquinolones remain the preferred initial drug therapy.[13]

Dietary considerations

Keeping the patient well hydrated is important, especially if an obstruction was recently relieved.

Drinking cranberry juice (10 oz/d) may offer some benefit and does not appear to be harmful. It appears to inhibit E coli from adhering to human uroepithelium; the amounts of bacteriostatic hippuric acid that are present are unlikely to be clinically effective.

For complicated UTIs associated with struvite calculi, foods and vitamin supplements rich in phosphorus and magnesium are advised. Remember that divalent cations (eg, magnesium) can chelate oral fluoroquinolones, preventing their absorption from the gut.

Activity considerations

Bedrest and avoiding certain activities (eg, bike riding) may be beneficial in patients with prostatitis. For patients with category IIIB (chronic, noninflammatory, abacterial) prostatitis, bedrest for 2 weeks has been advocated. Sitting on ring cushions can be a simple way to minimize symptoms.

In urethritis, sexual activity may be resumed when both partners have completed treatment; barrier methods are encouraged. No one knows for certain when sexual activity may be resumed for the other topics discussed in this article.

Previous
Next

Overview of Prostatitis Treatment

To eradicate prostatitis, therapeutic drug levels must be achieved within the prostatic acini. Other challenges include prostatic calculi (a nidus for infection), inspissated secretions and microabscesses, and biofilms produced by offending organisms. Bladder outlet obstruction promotes stasis (and thus infection).

Antimicrobial agents

Nitrofurantoin, sulfonamides, vancomycin, penicillins, and cephalosporins do not penetrate well into the prostate, although carbenicillin cures approximately 60% of patients with chronic bacterial prostatitis.

Antibiotics that penetrate well into the acid milieu of the prostate are nonpolar and lipid-soluble and have a high measure of acid strength, a small molecular radius, and low serum protein binding. Drugs that best fit these criteria are the fluoroquinolones, doxycycline, trimethoprim, rifampin, and erythromycin. Of this group, the fluoroquinolones appear to achieve the best tissue levels.

Quinolones can be divided into first, second, third, and fourth generations. First-generation drugs (nalidixic acid) are not effective for prostatic infections. Third-generation and fourth-generation fluoroquinolones provide increased streptococcal and anaerobic coverage, which is not needed to treat prostatic infections.

The second-generation quinolones widely used to treat prostatic infection include ciprofloxacin, ofloxacin, norfloxacin, and levofloxacin. These drugs all are bactericidal against gram-negative bacilli; however, because of increased resistance, they are no longer recommended by the CDC for N gonorrhoeae infections.[14] Levofloxacin is most effective against susceptible strains of Enterococcus faecalis and has the advantage of once-daily dosing. Although all of the second-generation drugs are used to treat prostatitis, only ofloxacin is approved by the US Food and Drug Administration (FDA) for this indication.

Doxycycline, trimethoprim-sulfamethoxazole (TMP-SMZ), and erythromycin are often used as second-line agents, especially when culture-directed therapy is possible. Of note, only the trimethoprim (and not sulfamethoxazole) readily penetrates the prostate.

Regarding antibiotic concentrations in the prostate, interpreting the literature is difficult because many different terms are used (eg, "mean concentration in prostatic tissue," "mean concentration in prostatic fluid, prostatic tissue/serum ratio, prostatic fluid/serum ratio," and "stromal/epithelial ratio"); furthermore, these specimens are often obtained in patients with benign prostatic hypertrophy or carcinoma (ie, not prostatitis). One also must note the host being tested; TMP-SMZ penetrates the dog prostate far better than the human prostate, probably because of differences in semen pH. Although some antibiotics appear to be more suitable by certain criteria, clinical efficacy is probably the bottom line.

Nonantimicrobial agents

Many nonantimicrobial modalities of therapy are available for prostatitis. Narcotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and tricyclic antidepressants (TCAs) (eg, amitriptyline) may be needed for pain relief. Hormonal manipulation with a 5-alpha-reductase inhibitor (finasteride) may decrease glandular inflammation; lycopene, prominent in tomato sauces, may also diminish glandular swelling.

Diazepam and baclofen may decrease sphincter or perineal muscle spasm. Alpha-blockers may minimize ductal reflux and dysfunctional voiding. However, conflicting evidence suggests that allopurinol may reduce prostatic urate reflux.

Saw palmetto is a popular herbal remedy for prostate problems, and small studies have suggested benefit; this agent warrants further study.

Nonpharmaceutical therapy

Nonpharmaceutical approaches may also be used for prostatitis. An example of "what's old is new" is prostate massage. For decades, prostate massage was the primary therapy for prostatitis, but it was largely abandoned in the antibiotic era. More clinicians now are using repetitive prostate massage; this treatment may improve circulation and antibiotic penetration, and it may help drain clogged ducts.

Applications of heat can be beneficial, but some of the techniques (transrectal and transurethral) limit its widespread application; hot sitz baths are simple and help, probably by relaxing muscle spasms.

Biofeedback, relaxation exercises, acupuncture, massage therapy, and chiropractic manipulation may be beneficial.

Previous
Next

Acute and Chronic Prostatitis Therapy

The primary management of prostatitis is medical therapy. In certain circumstances, however, surgical intervention may be required.

Acute bacterial prostatitis

The intensely inflamed prostate allows antimicrobials to easily pass from the plasma. Hospitalized patients with acute bacterial prostatitis could receive various antimicrobials; parenteral ampicillin and gentamicin are often used. In most cases, the fever resolves in 2 days.

Once improved, appropriate oral agents include TMP-SMZ or a fluoroquinolone (preferred). Therapy should be continued for a minimum of 4 weeks to prevent chronic bacterial prostatitis from developing. Analgesics and stool softeners may be helpful.

If the patient with acute prostatitis has significant urinary obstruction, a Foley catheter can be gently inserted. If this is too uncomfortable, a suprapubic cystotomy may be required. The catheter can usually be removed 1-2 days later.

Chronic bacterial prostatitis

Although chronic bacterial prostatitis is very difficult to cure medically, an attempt should be made to cure this condition with antimicrobial therapy.[15, 16, 17, 18] Long-term results with TMP-SMZ (15-60% cure rate) probably reflect the inability of sulfa drugs to penetrate the noninflamed prostate; the usual regimen is 1 double-strength TMP-SMZ dose twice a day for 3 months. The combination of trimethoprim with rifampin may be useful but needs further study in chronic bacterial prostatitis. Some evidence suggests that 30 days of a fluoroquinolone may be superior to TMP-SMZ.

Coverage for Chlamydia and Ureaplasma should be considered for patients with category IIIA prostatitis (ie, leukocytosis without demonstrable bacteria).

If therapy fails, appropriate management of chronic bacterial prostatitis is to either treat acute exacerbations or to try chronic suppressive therapy (using half-normal doses).

Antimicrobials are not needed for asymptomatic patients who have evidence of inflammation on biopsy specimens or in secretions (category IV prostatitis); however, antimicrobials should be considered for men who are infertile who have bacteria or inflammation in their semen.

Surgery is indicated only for a few specific conditions, including bladder neck obstruction, prostatic calculi (see the image below), and recurrent infection with the same bacteria.

Prostatic calcifications in a male with a urinary Prostatic calcifications in a male with a urinary tract infection.

Transurethral incision of the bladder neck benefits some patients with bladder neck obstruction; however, transurethral balloon dilatation of the prostate is not helpful. A partial transurethral prostatectomy (TURP) removes only part of the infected gland and thus, benefits only one third of patients.

Radical or total prostatectomy is usually not required or beneficial; complications include incontinence and impotence. Patients for whom a radical TURP or total prostatectomy should be considered are those with either prostatic calculi or those in whom the same bacteria have been consistently isolated from prostatic specimens. A prostate biopsy may confirm that the bacteria are actually originating from the prostate. These are rarely cured by antimicrobials alone; drainage is best achieved by an ultrasound-guided needle.

Other surgical interventions may be needed to remove or address other complications, such as bladder calculi, as shown in the following image.

Bladder calculi in a male with a urinary tract infBladder calculi in a male with a urinary tract infection.
Previous
Next

Epididymitis Therapy

For epididymitis, antibiotic treatment for patients younger than 35 years should target Chlamydia and gonococci. Ceftriaxone (intramuscular [IM] 250 mg) followed by doxycycline (oral [PO] 100 mg twice daily [bid] for 7-10 d) is usually effective.

Epididymitis therapy for older men should address enteric gram-negative rods. TMP-SMZ (double-strength, 1 dose PO bid) or a fluoroquinolone can be used; a 30-day course covers concomitant prostatic infection.

When risk factors for urosepsis are present, such as fever or urinary retention, the patient should be hospitalized and intravenous (IV) antibiotics should be started.

Of cases of acute scrotum, 90% are caused by epididymitis, torsion of the spermatic chord, and torsion of a testicular appendage.

Torsion of the spermatic cord must be assumed until proven otherwise, because unresolved torsion of the cord is likely to result in irreversible necrosis in less than 12 hours. Consultation with a urologist is mandatory in all but the most clear-cut cases for operative salvage of the torsed testicle.

The surgical intervention is detorsion and orchidopexy, with orchidopexy of the contralateral side (because this side is predisposed to torsion at a later date).

Previous
Next

Orchitis Therapy

For viral orchitis, supportive therapy with scrotal support, cold compresses, and bedrest is all that is needed. The use of estrogens, gammaglobulin, and steroids has been advocated by some, but these have not been shown to decrease the risk of sterility or shorten the duration of symptoms. Symptoms usually resolve spontaneously in 7-10 days.

Previous
Next

Pyelonephritis Therapy

Most patients with pyelonephritis should undergo imaging studies to rule out other lesions, and IV antibiotic treatment should be initiated empirically with an aminoglycoside and ampicillin. Third-generation and fourth-generation cephalosporins, a carbapenem, or aztreonam also provides broad gram-negative rod coverage.

Fluid resuscitation is important if the blood pressure is unstable or if the patient is very old.

IV antibiotics are usually continued until the patient is afebrile for 24 hours, and then oral therapy is prescribed to complete at least 14 days of treatment; usually 30 days of treatment are necessary because most cases are due to chronic prostatitis.

Urologic consultation should be considered for patients whose condition does not respond rapidly to antibiotics. In one study, fever persisted for 3 days in 13% of hospitalized patients with pyelonephritis, but none had complications; prolonged fever was associated with high baseline creatinine levels, younger age, and a high peripheral white blood cell (WBC) count.

Emphysematous pyelonephritis

Patients with diabetes are prone to develop emphysematous pyelonephritis, which is characterized by gas formation in the urinary tract. It often requires immediate nephrectomy for survival.

Previous
Next

Cystitis Therapy

For the few men with uncomplicated cystitis, TMP-SMZ can be used in areas where resistant E coli number less than 20%; alternatively, a fluoroquinolone can be used. The length of treatment should be 7-10 days.

Previous
Next

Urethritis Therapy

For urethritis, ceftriaxone (125 mg IM as a single dose) treats penicillinase-producing N gonorrhoeae. Treatment for nongonococcal urethritis (NGU) should also be given (doxycycline 100 mg PO bid for 7 d).

Sexual partners should also be treated, and patient counseling regarding safe sex is paramount; cases need to be reported to public health departments.

Previous
Next

Complications

Complications of acute bacterial prostatitis include bacteremia, septic shock, prostatic abscess, epididymitis, seminal vesiculitis, and pyelonephritis. Suspect a prostate abscess if fever does not resolve within 48 hours; if confirmed, add anaerobic coverage and arrange for drainage.

Both NGU and gonococcal urethritis may progress to prostatitis, epididymitis, and orchitis, especially in younger patients. Urethral strictures (secondary to inflammation within the urinary tract) may form in up to 5% of patients; this must be kept in mind when evaluating patients with residual obstructive symptoms after treatment.

Other complications from UTI include fistula formation, recurrent infection, bacteremia, hydronephrosis and pyonephrosis, and gram-negative sepsis. Pyonephrosis refers to infected hydronephrosis associated with suppurative destruction of the kidney parenchyma, which results in nearly total loss of renal function.

Previous
Next

Prevention

Preprocedure prophylaxis, condom use, and appropriate use of urinary catheters can reduce the risk of infections and complications.

Unfortunately, instillation of antimicrobial agents into the bladder (unidirectional flow from the bladder to the bag is best), placing antimicrobials in the urine-drainage bag (which breaks the closed-drainage system), use of methenamine, and rigorous meatal cleansing are of little benefit. The IDSA guideline advises against the routine addition of antimicrobials or antiseptics to the drainage bag of patients who are catheterized in an effort to reduce the risk of catheter-associated bacteriuria or CAUTI.[2]

Preoperative prophylaxis

Preoperative antibiotics can reduce complications. Procedures of concern include open, transurethral, or laser prostatectomy; transrectal prostate biopsy; cystoscopy in patients with preoperative bacteruria or a preoperative indwelling catheter, or renal transplantation. Before antibiotic coverage, the rate of septicemia from a transrectal biopsy was 5-10%; currently, the rate is less than 0.1%. Fluoroquinolones are the prophylactic drugs of choice for urologic procedures.

Post-transurethral prostatectomy (TURP) bacteriuria rates are approximately 10% in those who receive systemic antibiotics, compared to approximately 35% in those who do not. Single-dose therapy is as effective as longer courses.

Unfortunately, neither cefuroxime nor ciprofloxacin was shown to reduce the rate of bacteriuria (approximately 20%) after lithotripsy.

The American Heart Association recommends antimicrobial prophylaxis to prevent bacterial endocarditis in patients with moderate- to high-risk cardiac conditions. High-risk conditions include prosthetic valves, previous bacterial endocarditis, complex cyanotic congenital heart diseases, and surgically constructed systemic pulmonic shunts. Moderate-risk conditions include most other congenital heart diseases, hypertrophic cardiac myopathy, and mitral prolapse with regurgitation. For patients with moderate- or high-risk cardiac conditions, urologic procedures that warrant prophylaxis include prostate surgery, cystoscopy, and urethral dilatation; prophylaxis is not recommended for inserting a Foley catheter in a patient with uninfected urine.

Antibiotic regimens

Regimens for high-risk patients include ampicillin (or vancomycin) plus gentamicin. Ampicillin is given as 2000 mg IM or IV within 30 minutes of starting the procedure; 6 hours later, 1000 mg of ampicillin (or amoxicillin PO) is given once. Gentamicin is dosed at 1.5 mg/kg IV or IM (not to exceed 120 mg) and is given only once with the first dose of ampicillin. For patients allergic to ampicillin, 1000 mg of vancomycin is given IV over 1-2 hours only once; it should be completed within 30 minutes of starting the procedure.

For kidney transplant recipients, TMP/SMZ (1 dose PO qd) beginning 2-4 days after surgery and continuing for 4-8 months reduced the incidence rate of UTIs from 38% to 8% (especially after the catheter was removed), cut febrile hospital days and bacterial infections (during and after hospitalization) in half, and reduced graft rejection.

Regimens for moderate-risk patients include amoxicillin or vancomycin. Amoxicillin is given only once as 2000 mg PO, 1 hour before the procedure. For patients allergic to amoxicillin, 1000 mg of vancomycin is given IV over 1-2 hours only once; it should be completed within 30 minutes of starting the procedure.

Prevention of STD–related infections

Condoms are useful in preventing sexually transmitted diseases (STD) such as urethritis; latex condoms help prevent the transmission of human immunodeficiency virus (HIV). Remember that these patients are at risk for more than one infection (gonorrhea, chlamydia, syphilis, hepatitis B, herpes, Trichomonas, HIV). The risk of acquiring HIV from an infected sexual partner is approximately 0.3% on average; the risk is 30-50% for herpes and gonorrhea. If abstaining is not an option, condoms are the best protection.

Prevention of CAUTIs

The CDC 2009 guideline on CAUTIs states that catheter use and duration should be minimized in all patients, especially those at higher risk for CAUTI (women, elderly persons, and patients with impaired immunity).[3] According to the IDSA 2009 guideline, strategies to reduce the use of catheterization are proven effective and may have more impact on the incidence of CAUTI and asymptomatic bacteriuria than other approaches addressed in the guidelines.[2]

Appropriate indications for indwelling urethral catheters include the relief of bladder outlet obstruction, treating urinary incontinence in a patient with an open sacral wound, monitoring urine output, and during prolonged surgical procedures.

At least 7 steps can be taken to prevent CAUTIs; these steps can postpone a UTI for weeks, but they will not be totally successful in patients with long-term catheterization:

  1. Catheterization should be avoided when not required (catheters were found to be unnecessary in 41-58% of patient-days) and should be terminated as soon as possible.
  2. Suprapubic catheters are associated with a lower risk of UTI. For men who require long-term catheterization, local genitourinary complications (meatal erosion, prostatitis, epididymitis) may be reduced and patients may be more satisfied, but mechanical complications are increased. Contraindications include bleeding disorders, previous lower abdominal surgery or irradiation, and morbid obesity.
  3. Condom catheters are also associated with a lower risk of bacteriuria than indwelling catheters, as long as the catheter is not manipulated frequently. However, these are difficult to use in uncircumcised men.
  4. Most patients using intermittent catheterization become bacteriuric within a few weeks. The incidence rate is 1-3% per insertion.
  5. Aseptic indwelling catheter insertion, a properly maintained closed-drainage system (with ports in the distal catheter for needle aspiration of urine[2] ) and unobstructed urine flow are essential. Catheters with hydrophilic coatings reduce or delay the onset of bacteriuria and are more comfortable for the patient. Only properly trained individuals who are skilled in the correct technique of aseptic catheter insertion and maintenance should take on this task.[3]
  6. Urinary catheters coated with silver also reduce the risk of CAUTIs. Silver alloy seems to be more effective than silver oxide, and using these more expensive catheters in those who are at highest risk is reasonable.[19]
  7. Because many CAUTIs occur in clusters, good handwashing before and after catheter care is essential.

Go to Urinary Catheterization in Men and Urinary Catheterization in Women for procedural information on these topics.

Previous
Next

Special Considerations

In cases of mumps orchitis, the patient and his family should be advised that sterility develops in up to 10% of affected individuals. Because no treatment is available for this entity, it is important that the measles-mumps-rubella (MMR) vaccine is given in childhood and repeated in late adolescence.

Testicular cancer is the most common malignancy in males aged 15-35 years. Although it usually presents as a painless intraparenchymal mass, 10% of cases present after minor trauma. For this reason, any patient felt to have a lesion within the parenchyma of the testicle should be referred for immediate urologic evaluation.

Many lawsuits arise from the complications of long-term aminoglycosides, especially irreversible cranial nerve VIII damage (hearing loss and vestibular dysfunction).

Complication risk factors appear to be prolonged use of aminoglycosides (>2 wk), high serum trough levels (>2), advanced age, baseline renal insufficiency, concomitant conditions (eg, diabetes mellitus), and concomitant nephrotoxic drugs (eg, amphotericin B).

Fortunately, most aminoglycoside use in treating serious UTIs is limited to less than 1 week. Unfortunately, monitoring for cranial nerve VIII dysfunction is less than optimal; by the time it is detectable (even subclinically, by weekly audiograms and/or electronystagmograms), the damage has been done and is irreversible. This is because of differences in half-lives between sera and because of the endolymph and perilymph that bathe the inner ear. However, monitoring allows the damage to be minimized. Remember that the auditory and vestibular systems function independently; therefore, consideration should be given to monitoring each.

Animal models suggest that doses of aminoglycosides given at night or to a patient who has been fasting or is dehydrated may be more ototoxic. The possibly protective roles of calcium and calcium channel blockers await further study.

Previous
Next

Consultations

A urologist is essential for UTIs in adult males with the following:

  • A suspected underlying anatomic abnormality. However, this consultation can be completed on an outpatient basis, unless obstructive uropathy is present.
  • In all but the most clear-cut cases of acute scrotum
  • In all forms of prostatitis: In acute bacterial prostatitis, suprapubic drainage may be required if acute urinary retention occurs.

The following are suggested consultations:

  • An infectious disease specialist, when unusual or resistant microorganisms have been isolated or if the infection is in an unusual host
  • A specialist in pharmacokinetics, when using aminoglycosides
  • The patient's primary care provider

Pain specialists may be needed to control discomfort in patients with nonbacterial prostatitis. Chronic abacterial prostatitis shares the following with other chronic pain syndromes: (1) pain as a primary complaint; (2) discord between symptoms and findings; and (3) history of multiple, unsuccessful treatments. Providers of alternative healing (eg, hypnotherapists) and a psychiatrist or psychologist also may be needed.

Previous
Next

Long-Term Monitoring

If a patient fails to respond to antibiotics, an abscess should be considered. Upper- and lower-tract studies (eg, intravenous pyelography [IVP], cystoscopy) are important to consider in older patients at risk for anatomic abnormalities.

Follow-up urine cultures are warranted in males with UTIs; however, follow-up urethral cultures are not routinely warranted unless the man is symptomatic, in which case the symptoms are likely to be the result of exogenous reinfection.

Consider admission for urinary tract infection for elderly patients and patients who have diabetes, who are immunocompromised, or who show signs of toxicity such as dehydration, hyperpyrexia, rigors, or inability to tolerate oral fluids or medications. Also admit if the patient is unable to care for himself.

Previous
Proceed to Medication
 
 
Contributor Information and Disclosures
Author

John L Brusch, MD, FACP  Assistant Professor of Medicine, Harvard Medical School; Consulting Staff, Department of Medicine and Infectious Disease Service, Cambridge Health Alliance

John L Brusch, MD, FACP is a member of the following medical societies: American College of Physicians and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Coauthor(s)

Burke A Cunha, MD  Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

David S Howes, MD  Professor of Medicine and Pediatrics, Section Chief and Emergency Medicine Residency Program Director, University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine

David S Howes, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American College of Physicians-American Society of Internal Medicine, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

M Tyson Pillow, MD  Assistant Director of Medical Education, Ben Taub General Hospital Emergency Center; Assistant Professor, Baylor College of Medicine

M Tyson Pillow, MD is a member of the following medical societies: Air Medical Physician Association, American College of Emergency Physicians, American Medical Association, American Medical Student Association/Foundation, Emergency Medicine Residents Association, Society for Academic Emergency Medicine, and Student National Medical Association

Disclosure: Nothing to disclose.

Joseph A Salomone III, MD  Associate Professor and Attending Staff, Truman Medical Centers, University of Missouri-Kansas City School of Medicine; EMS Medical Director, Kansas City, Missouri

Joseph A Salomone III, MD is a member of the following medical societies: American Academy of Emergency Medicine, National Association of EMS Physicians, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Richard H Sinert, DO  Associate Professor of Emergency Medicine, Clinical Assistant Professor of Medicine, Research Director, State University of New York College of Medicine; Consulting Staff, Department of Emergency Medicine, Kings County Hospital Center

Richard H Sinert, DO is a member of the following medical societies: American College of Physicians and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Klaus-Dieter Lessnau, MD, FCCP  Clinical Associate Professor of Medicine, New York University School of Medicine; Medical Director, Pulmonary Physiology Laboratory; Director of Research in Pulmonary Medicine, Department of Medicine, Section of Pulmonary Medicine, Lenox Hill Hospital

Klaus-Dieter Lessnau, MD, FCCP is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Medical Association, American Thoracic Society, and Society of Critical Care Medicine

Disclosure: Sepracor None None

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Mark Jeffrey Noble, MD  Consulting Staff, Urologic Institute, Cleveland Clinic Foundation

Mark Jeffrey Noble, MD is a member of the following medical societies: American College of Surgeons, American Medical Association, American Urological Association, Kansas Medical Society, Sigma Xi, Society of University Urologists, and Southwest Oncology Group

Disclosure: Nothing to disclose.

Erik D Schraga, MD  Staff Physician, Department of Emergency Medicine, Mills-Peninsula Emergency Medical Associates

Disclosure: Nothing to disclose.

Chief Editor

Michael Stuart Bronze, MD  Professor, Stewart G Wolf Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center

Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physician Executives, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Federation for Clinical Research, American Medical Association, American Society for Microbiology, Association of Professors of Medicine, Association of Program Directors in Internal Medicine, Infectious Diseases Society of America, Oklahoma State Medical Association, and Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Acknowledgments

The authors and editors of eMedicine gratefully acknowledge the contributions of previous authors Cindy L Tamminga, MD, and Bryan P Blair, MD, to the development and writing of a source article.

References
  1. Meares EM, Stamey TA. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol. Mar 1968;5(5):492-518. [Medline].

  2. [Guideline] Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis. Mar 1 2010;50(5):625-63. [Medline]. [Full Text].

  3. [Guideline] Gould CV, Umscheid CA, Agarwal RK, Kuntz G, Pegues DA. Guideline for prevention of catheter-associated urinary tract infections 2009. Infect Control Hosp Epidemiol. Apr 2010;31(4):319-26. [Medline]. [Full Text].

  4. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. Jul 8 2002;113 Suppl 1A:5S-13S. [Medline].

  5. Johnson JR. Laboratory diagnosis of urinary tract infections in adult patients. Clin Infect Dis. Sep 15 2004;39(6):873; author reply 873-4. [Medline].

  6. McNaughton Collins M, Fowler FJ Jr, Elliott DB, Albertsen PC, Barry MJ. Diagnosing and treating chronic prostatitis: do urologists use the four-glass test?. Urology. Mar 2000;55(3):403-7. [Medline].

  7. Nickel JC. The Pre and Post Massage Test (PPMT): a simple screen for prostatitis. Tech Urol. Spring 1997;3(1):38-43. [Medline].

  8. Daunt SW. Accuracy of ultrasonography and plain-film abdominal radiography in the diagnosis of urologic abnormalities in men with urinary tract infection: critically appraised topic. Can Assoc Radiol J. Feb 2004;55(1):16-7. [Medline].

  9. Guay DR. Contemporary management of uncomplicated urinary tract infections. Drugs. 2008;68(9):1169-205. [Medline].

  10. Howes DS, Bogner MP. Urinary tract infections. In: Tintinalli JE, Kelen GD, Stapczyski JS, eds. Emergency Medicine: A Comprehensive Study Guide. 7th ed. New York, NY: McGraw-Hill; 2008.

  11. Talan DA, Krishnadasan A, Abrahamian FM, Stamm WE, Moran GJ. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin Infect Dis. Nov 1 2008;47(9):1150-8. [Medline].

  12. Cunha BA. Antibiotic Essentials. 7th ed. Royal Oak, Mich: Physicians Press.; 2008.

  13. Killgore KM, March KL, Guglielmo BJ. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother. Jul-Aug 2004;38(7-8):1148-52. [Medline].

  14. [Guideline] Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. Aug 4 2006;55:1-94. [Medline]. [Full Text].

  15. Wagenlehner FM, Naber KG. Fluoroquinolone Antimicrobial Agents in the Treatment of Prostatitis and Recurrent Urinary Tract Infections in Men. Curr Infect Dis Rep. Jan 2005;7(1):9-16. [Medline].

  16. Wagenlehner FM, Naber KG. Current challenges in the treatment of complicated urinary tract infections and prostatitis. Clin Microbiol Infect. May 2006;12 Suppl 3:67-80. [Medline].

  17. Luzzi G. Chronic prostatitis. N Engl J Med. Jan 25 2007;356(4):423-4; author reply 424. [Medline].

  18. Wagenlehner FM, Weidner W, Naber KG. Therapy for prostatitis, with emphasis on bacterial prostatitis. Expert Opin Pharmacother. Aug 2007;8(11):1667-74. [Medline].

  19. Saint S, Elmore JG, Sullivan SD, Emerson SS, Koepsell TD. The efficacy of silver alloy-coated urinary catheters in preventing urinary tract infection: a meta-analysis. Am J Med. Sep 1998;105(3):236-41. [Medline].

  20. [Guideline] CDC. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep. Apr 13 2007;56(14):332-6. [Medline]. [Full Text].

  21. Chiang IN, Chang SJ, Pu YS, Huang KH, Yu HJ, Huang CY. Major complications and associated risk factors of transrectal ultrasound guided prostate needle biopsy: a retrospective study of 1875 cases in taiwan. J Formos Med Assoc. Nov 2007;106(11):929-34. [Medline].

  22. van der Starre WE, van Nieuwkoop C, Paltansing S, et al. Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection. J Antimicrob Chemother. Mar 2011;66(3):650-6. [Medline].

Previous
Next
 
Prostatic calcifications in a male with a urinary tract infection.
Bladder calculi in a male with a urinary tract infection.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.